DongKoo Bio & Pharma Co. Ltd. (006620) - Net Assets
Based on the latest financial reports, DongKoo Bio & Pharma Co. Ltd. (006620) has net assets worth ₩142.58 Billion KRW (≈ $96.62 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩318.60 Billion ≈ $215.91 Million USD) and total liabilities (₩176.02 Billion ≈ $119.29 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DongKoo Bio & Pharma Co. Ltd. PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩142.58 Billion |
| % of Total Assets | 44.75% |
| Annual Growth Rate | 50.5% |
| 5-Year Change | 51.97% |
| 10-Year Change | 590.22% |
| Growth Volatility | 223.14 |
DongKoo Bio & Pharma Co. Ltd. - Net Assets Trend (2015–2025)
This chart illustrates how DongKoo Bio & Pharma Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of DongKoo Bio & Pharma Co. Ltd..
Annual Net Assets for DongKoo Bio & Pharma Co. Ltd. (2015–2025)
The table below shows the annual net assets of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025. Also explore DongKoo Bio & Pharma Co. Ltd. annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩152.16 Billion ≈ $103.12 Million |
+44.46% |
| 2024-12-31 | ₩105.33 Billion ≈ $71.38 Million |
-4.63% |
| 2023-12-31 | ₩110.44 Billion ≈ $74.85 Million |
+8.17% |
| 2022-12-31 | ₩102.11 Billion ≈ $69.20 Million |
+1.98% |
| 2021-12-31 | ₩100.12 Billion ≈ $67.85 Million |
+5.78% |
| 2020-12-31 | ₩94.65 Billion ≈ $64.14 Million |
+10.51% |
| 2019-12-31 | ₩85.65 Billion ≈ $58.05 Million |
+18.80% |
| 2018-12-31 | ₩72.10 Billion ≈ $48.86 Million |
+91.01% |
| 2017-12-31 | ₩37.74 Billion ≈ $25.58 Million |
+71.22% |
| 2016-12-31 | ₩22.05 Billion ≈ $14.94 Million |
+764.45% |
| 2015-12-31 | ₩2.55 Billion ≈ $1.73 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DongKoo Bio & Pharma Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11468273323000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩114.06 Billion | 75.19% |
| Other Components | ₩37.64 Billion | 24.81% |
| Total Equity | ₩151.70 Billion | 100.00% |
DongKoo Bio & Pharma Co. Ltd. Competitors by Market Cap
The table below lists competitors of DongKoo Bio & Pharma Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CESSATECH A/S DK -20
F:8GN
|
$22.85 Million |
|
Is Girisim Sermayesi Yatirim Ortakligi AS
IS:ISGSY
|
$22.85 Million |
|
Gryphon Digital Mining Inc.
NASDAQ:GRYP
|
$22.85 Million |
|
Fold Holdings, Inc. Class A Common Stock
NASDAQ:FLD
|
$22.86 Million |
|
Rig Tenders Tbk
JK:RIGS
|
$22.84 Million |
|
Nissan
TA:NISA
|
$22.84 Million |
|
Microba Life Sciences Ltd
AU:MAP
|
$22.84 Million |
|
Honey Badger Silver Inc
V:TUF
|
$22.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DongKoo Bio & Pharma Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 105,331,586,000 to 151,702,251,680, a change of 46,370,665,680 (44.0%).
- Net income of 50,272,415,030 contributed positively to equity growth.
- Dividend payments of 3,245,052,960 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩50.27 Billion | +33.14% |
| Dividends Paid | ₩3.25 Billion | -2.14% |
| Other Changes | ₩-656.70 Million | -0.43% |
| Total Change | ₩- | 44.02% |
Book Value vs Market Value Analysis
This analysis compares DongKoo Bio & Pharma Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.25x to 0.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1080.29 | ₩3510.00 | x |
| 2017-12-31 | ₩1656.17 | ₩3510.00 | x |
| 2018-12-31 | ₩2509.16 | ₩3510.00 | x |
| 2019-12-31 | ₩3027.49 | ₩3510.00 | x |
| 2020-12-31 | ₩3345.60 | ₩3510.00 | x |
| 2021-12-31 | ₩3570.78 | ₩3510.00 | x |
| 2022-12-31 | ₩3696.33 | ₩3510.00 | x |
| 2023-12-31 | ₩3996.59 | ₩3510.00 | x |
| 2024-12-31 | ₩3815.25 | ₩3510.00 | x |
| 2025-12-31 | ₩5609.85 | ₩3510.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DongKoo Bio & Pharma Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 33.14%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.71%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 2.22x
- Recent ROE (33.14%) is above the historical average (30.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 158.01% | 5.01% | 1.32x | 23.83x | ₩3.77 Billion |
| 2016 | 49.50% | 12.49% | 1.34x | 2.96x | ₩8.71 Billion |
| 2017 | 28.99% | 10.82% | 1.34x | 2.00x | ₩7.17 Billion |
| 2018 | 6.34% | 4.36% | 1.01x | 1.45x | ₩-2.64 Billion |
| 2019 | 17.63% | 12.06% | 0.94x | 1.55x | ₩6.54 Billion |
| 2020 | 9.66% | 6.57% | 0.96x | 1.53x | ₩-324.82 Million |
| 2021 | 9.32% | 6.01% | 1.00x | 1.55x | ₩-685.84 Million |
| 2022 | 6.48% | 3.39% | 1.13x | 1.69x | ₩-3.60 Billion |
| 2023 | 10.70% | 5.48% | 1.13x | 1.73x | ₩771.64 Million |
| 2024 | 1.93% | 0.82% | 1.02x | 2.32x | ₩-8.50 Billion |
| 2025 | 33.14% | 20.71% | 0.72x | 2.22x | ₩35.10 Billion |
Industry Comparison
This section compares DongKoo Bio & Pharma Co. Ltd.'s net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $79,433,880,023
- Average return on equity (ROE) among peers: -6.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DongKoo Bio & Pharma Co. Ltd. (006620) | ₩142.58 Billion | 158.01% | 1.23x | $22.84 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $2.37 Billion |
| NatureCell Co.Ltd (007390) | $62.68 Billion | -30.10% | 0.37x | $884.84 Million |
| Sam-A Pharm. Co. Ltd (009300) | $79.92 Billion | 4.39% | 0.39x | $57.91 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $226.71 Billion | 8.88% | 0.27x | $80.33 Million |
| WooGene B&G Co. Ltd (018620) | $18.56 Billion | 6.88% | 0.41x | $47.07 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $713.20 Million |
| EstechPharma Co. Ltd (041910) | $89.25 Billion | 7.38% | 0.10x | $43.30 Million |
| Komipharm International Co. Ltd (041960) | $65.54 Billion | 20.01% | 0.87x | $370.23 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $29.11 Billion | 3.53% | 0.43x | $26.69 Million |
About DongKoo Bio & Pharma Co. Ltd.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more